Medicaid drug reimbursement policy is set by state agencies operating under federal minimum standards, with the specific details of dispensing fees, NADAC-based ingredient cost benchmarks, and managed care pharmacy carve-in or carve-out arrangements varying substantially across states. The federal government introduced NADAC as the preferred ingredient cost benchmark for fee-for-service Medicaid drug reimbursement, replacing the older Average Wholesale Price and Wholesale Acquisition Cost benchmarks that had been widely criticized as systematically overstating actual pharmacy acquisition costs. What the federal government did not do is provide states with a systematic tool for monitoring whether their NADAC-based reimbursement formulas are producing adequate pharmacy access—particularly in rural areas and for high-cost generic categories experiencing acquisition cost inflation.
How States Currently Use NADAC Data
Most state Medicaid agencies use NADAC as a pricing reference: a weekly updated benchmark that determines the ingredient cost component of their fee-for-service drug reimbursement. The pharmacy submits a claim for a specific drug, the state looks up the current NADAC for that NDC, applies the established dispensing fee, and reimburses accordingly. The process is automated and transaction-level—there is no systematic analysis of NADAC trends across drug categories, no monitoring of whether aggregate reimbursement adequacy is deteriorating, and no alert system for when specific drug categories enter zones of negative margin reimbursement.
MedPricer’s analytical approach—tracking NADAC trends across time and drug categories—is precisely the kind of population-level analysis that would allow state policy makers to answer the question that the transaction-level system cannot: how many pharmacies in our state, serving our Medicaid population, are dispensing drugs at negative margin, in which categories, and for how long?
The Rural Pharmacy Access Problem
Rural pharmacy access has become a serious public health concern in states where independent pharmacies have closed at rates that leave significant geographic areas without a nearby dispensing point. The chain pharmacies that dominate urban markets have not filled the rural gaps, because the economics of high-volume, low-margin dispensing do not support rural location without a sufficient population density.
The relationship between Medicaid reimbursement adequacy—driven substantially by NADAC-based ingredient cost reimbursement and dispensing fee levels—and rural pharmacy closures is not well-documented empirically. MedPricer’s dataset could support exactly this analysis: correlating NADAC acquisition cost trends by drug category with dispensing fee adequacy by state, and mapping the result against pharmacy closure data to identify which state reimbursement configurations are associated with accelerating pharmacy attrition.
The Managed Care Question
Most Medicaid beneficiaries receive their pharmacy benefits through managed care organizations that contract with the state rather than through the fee-for-service system where NADAC-based reimbursement applies directly. In managed care, pharmacy reimbursement is negotiated between the MCO and its pharmacy network—NADAC informs those negotiations but does not determine them directly.
The opacity of MCO pharmacy contracting in Medicaid creates a policy monitoring problem: state Medicaid agencies know what they pay MCOs in premium rates, but they often have limited visibility into what MCOs are paying pharmacies within their networks. If MCO pharmacy reimbursement rates are diverging significantly from NADAC—either above or below—the state is either overpaying for pharmacy access or underpaying in ways that threaten network adequacy. MedPricer’s baseline NADAC data could anchor state oversight of MCO pharmacy contracting if states required MCOs to report their actual pharmacy reimbursement rates alongside NADAC benchmarks.
What a State-Level Pharmacy Access Dashboard Would Require
A state Medicaid program that wanted to use NADAC trend data systematically—to monitor reimbursement adequacy, identify geographic access risks, and inform dispensing fee policy—would need MedPricer’s normalized, categorized, trended NADAC data combined with state-specific pharmacy location data, dispensing volume data, and payer mix information. That combination is not currently available in any single system for any state.
Building it would require data sharing arrangements between CMS, state Medicaid agencies, and pharmacy data systems—the kind of interoperability effort that has proven technically possible but politically difficult in healthcare. MedPricer’s dataset provides the pharmaceutical pricing foundation for such a system. The policy will and the data governance infrastructure would need to come from elsewhere.
